Literature DB >> 10203586

Clinicopathological significance of erbB-2 expression in colorectal carcinoma.

N L Chamberlain1, R L Ward, N J Hawkins.   

Abstract

The level of erbB-2 expression in both the tumour tissue and serum of individuals with colorectal carcinoma is unclear. This study aims to clarify expression levels and to relate these to a range of clinicopathological parameters. Overexpression of erbB-2 was detected in 25% of patient tumour tissue and an elevation in serum concentration of the extracellular domain (ECD) of erbB-2 was detected in 10% of patients. Surprisingly, an elevated serum ECD concentration did not correlate with erbB-2 overexpression within the primary tumour, and neither tumour or serum levels of the protein correlated with any clinicopathological parameters examined. These results indicate that erbB-2 overexpression in tissue and serum are not uncommon in colorectal carcinoma, but may not be useful as predictors of disease outcome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10203586     DOI: 10.3892/or.6.3.527

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  4 in total

1.  TSPAN1 protein expression: a significant prognostic indicator for patients with colorectal adenocarcinoma.

Authors:  Li Chen; Yuan-Yuan Zhu; Xiao-Juan Zhang; Gui-Lan Wang; Xin-Yu Li; Song He; Jian-Bin Zhang; Jian-Wei Zhu
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

2.  Preoperative serum levels of c-erbB-2 do not seem to be useful in management of patients with rectal cancer.

Authors:  Dujo Kovacević; Zdenko Sonicki; Zvonko Kusić; Ante Bolanca; Goran Grubisić; Maja Lukac; Josip Lukac
Journal:  Int J Colorectal Dis       Date:  2006-11-22       Impact factor: 2.796

3.  Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas.

Authors:  Panteleimon Kountourakis; Kitty Pavlakis; Amanda Psyrri; Dimitra Rontogianni; Nikolaos Xiros; Efstratios Patsouris; Dimitrios Pectasides; Theofanis Economopoulos
Journal:  BMC Cancer       Date:  2006-02-28       Impact factor: 4.430

4.  c-erbB-2 is not a major factor in the development of colorectal cancer.

Authors:  J A McKay; J F Loane; V G Ross; M-M Ameyaw; G I Murray; J Cassidy; H L McLeod
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.